|
Alzheimer's Disease
|
0.090 |
Biomarker
|
disease |
BEFREE |
<b>:</b> It has long been established that mitochondrial dysfunction in Alzheimer's disease (AD) patients can trigger pathological changes in cell metabolism by altering metabolic enzymes such as the mitochondrial 17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10), also known as amyloid-binding alcohol dehydrogenase (ABAD).
|
31362457 |
2019 |
|
Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
17BetaHSD type 1 gene expression was detected in 34 of 42 adenomas in all tumor subtypes; 17betaHSD type 2 mRNA was detected in 18 of 42 adenomas, but not in prolactinomas; 17betaHSD type 3 mRNA was detected in 12 of 42 adenomas, but not in corticotropinomas; 17betaHSD type 4 was expressed in 20 of 42 adenomas by all adenoma subtypes.
|
10199776 |
1999 |
|
Prolactinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
17BetaHSD type 1 gene expression was detected in 34 of 42 adenomas in all tumor subtypes; 17betaHSD type 2 mRNA was detected in 18 of 42 adenomas, but not in prolactinomas; 17betaHSD type 3 mRNA was detected in 12 of 42 adenomas, but not in corticotropinomas; 17betaHSD type 4 was expressed in 20 of 42 adenomas by all adenoma subtypes.
|
10199776 |
1999 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
17HSD1 and 17HSD2 are the main 17HSD enzymes involved in breast cancer investigated this far, but it is possible that other hormone-regulating enzymes have a similar role.
|
17145895 |
2006 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
17HSD1 and 17HSD2 are the main 17HSD enzymes involved in breast cancer investigated this far, but it is possible that other hormone-regulating enzymes have a similar role.
|
17145895 |
2006 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
17beta-Hydroxysteroid dehydrogenase/17-ketosteroid reductases (17HSD/KSR) play a key role in regulating steroid receptor occupancy in normal tissues and tumors.
|
12361724 |
2002 |
|
Malignant tumor of colon
|
0.020 |
Biomarker
|
disease |
BEFREE |
17Beta-hydroxysteroid dehydrogenase type 2: independent prognostic significance and evidence of estrogen protection in female patients with colon cancer.
|
14672733 |
2003 |
|
Colon Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
17Beta-hydroxysteroid dehydrogenase type 2: independent prognostic significance and evidence of estrogen protection in female patients with colon cancer.
|
14672733 |
2003 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
17beta-hydroxysteroid dehydrogenase type 1 is an independent prognostic marker in breast cancer.
|
15492288 |
2004 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
17beta-hydroxysteroid dehydrogenase type 1 is an independent prognostic marker in breast cancer.
|
15492288 |
2004 |
|
Benign Prostatic Hyperplasia
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
17beta-Hydroxysteroid dehydrogenase (17beta-HSD) types 1, 2, 4, 7, and 12, as well as aromatase mRNA and protein expressions, were studied in benign prostatic hyperplasia (BPH) specimens using in situ hybridization and immunohistochemistry.
|
16651392 |
2006 |
|
Oestrogen receptor positive breast cancer
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
17beta-hydroxysteroid dehydrogenase 14 affects estradiol levels in breast cancer cells and is a prognostic marker in estrogen receptor-positive breast cancer.
|
17145895 |
2006 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
17Beta-hydroxysteroid dehydrogenase enzymes and breast cancer.
|
19167496 |
2009 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
17Beta-hydroxysteroid dehydrogenase enzymes and breast cancer.
|
19167496 |
2009 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
17Beta-hydroxysteroid dehydrogenase type 12 in human breast carcinoma: a prognostic factor via potential regulation of fatty acid synthesis.
|
19190350 |
2009 |
|
Progesterone Resistance
|
0.010 |
Biomarker
|
disease |
BEFREE |
17Beta-hydroxysteroid dehydrogenase-2 deficiency and progesterone resistance in endometriosis.
|
20108182 |
2010 |
|
Endometriosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
17Beta-hydroxysteroid dehydrogenase-2 deficiency and progesterone resistance in endometriosis.
|
20108182 |
2010 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
17beta-hydroxysteroid dehydrogenase type 1 stimulates breast cancer by dihydrotestosterone inactivation in addition to estradiol production.
|
20172961 |
2010 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
17beta-hydroxysteroid dehydrogenase type 1 stimulates breast cancer by dihydrotestosterone inactivation in addition to estradiol production.
|
20172961 |
2010 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
17beta-hydroxysteroid dehydrogenase type 1 modulates breast cancer protein profile and impacts cell migration.
|
22691413 |
2012 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
17beta-hydroxysteroid dehydrogenase type 1 modulates breast cancer protein profile and impacts cell migration.
|
22691413 |
2012 |
|
Invasive Ductal Breast Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
17β-hydroxysteroid dehydrogenase isoform 12 (HSD17B12) overexpression is associated with poor clinical outcome in invasive ductal carcinoma of the breast.
|
22903146 |
2012 |
|
Malignant neoplasm of prostate
|
0.060 |
Biomarker
|
disease |
BEFREE |
PRAP is a prostate cancer screening program for unaffected men ages 35-69 with a family history of prostate cancer or African descent.
|
24310616 |
2014 |
|
Prostate carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
PRAP is a prostate cancer screening program for unaffected men ages 35-69 with a family history of prostate cancer or African descent.
|
24310616 |
2014 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
17β-hydroxysteroid dehydrogenase (17β-HSD) type 1 is known as a critical target to block the final step of estrogen production in estrogen-dependent breast cancer.
|
25966904 |
2015 |